{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:34Z","timestamp":1788883714133,"version":"build-2803163510"},"reference-count":13,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Although venetoclax-based regimens are highly effective for patients with chronic lymphocytic leukemia (CLL), initiation is complex because of the requirement of a 5-week dose ramp-up used to mitigate the risk of tumor lysis syndrome (TLS). We report the results of the first prospective study of venetoclax initiation using an accelerated 5-day inpatient dose ramp-up in CLL. Forty patients were treated, including 15 (37.5%) with relapsed or refractory disease and 13 (32.5%) with medium (n = 11 [27.5%]) or high (n = 2 [5%]) TLS risk at enrollment. All except 1 (97.5%) received obinutuzumab in combination with venetoclax. All patients completed an accelerated daily venetoclax ramp-up from 20 to 400 mg in the inpatient setting. None had clinical TLS. One (2.5%) patient with Bruton tyrosine kinase inhibitor\u2013refractory CLL and high TLS risk developed laboratory TLS after the 200 mg dose of venetoclax, which normalized within a day with a 1-day dose hold and supportive care. The median inpatient time was 7 days. In intention-to-treat analyses of efficacy at 3 months, the overall response rate was 78.0%. Our data support the feasibility of accelerated venetoclax ramp-up in select patients in experienced centers and warrant further exploration of this approach in broader clinical settings. This trial was registered at www.clinicaltrials.gov as NCT04843904.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020392","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:56:45Z","timestamp":1782237405000},"page":"6009-6013","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer L.","family":"Crombie","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-287X","authenticated-orcid":false,"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":false,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Carey","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kniezewski","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Normilus","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantal","family":"Solomon","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Montegaard","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-0658","authenticated-orcid":false,"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-8584","authenticated-orcid":false,"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"4","key":"2026090811324040500_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090811324040500_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"23","key":"2026090811324040500_bib3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2026090811324040500_bib4","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1002\/ajh.26444","article-title":"A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Davids","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2026090811324040500_bib5","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2020002593","article-title":"Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists","volume":"4","author":"Koenig","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026090811324040500_bib6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2026090811324040500_bib7","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026090811324040500_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2026090811324040500_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"19","key":"2026090811324040500_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"2026090811324040500_bib11","first-page":"P868","article-title":"Reduction of tumor lysis syndrome (TLS) risk in chronic lymphocytic leukemia (CLL) patients treated with ABT-199 (GDC-0199): results of modifications to dosing schedule and TLS prophylaxis","volume":"54208","author":"Seymour","year":"2014","journal-title":"EHA Libr"},{"issue":"12","key":"2026090811324040500_bib12","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.medj.2025.100885","article-title":"Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b\/2 study","volume":"6","author":"Davids","year":"2025","journal-title":"Med"},{"issue":"suppl 1","key":"2026090811324040500_bib13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2025-2136","article-title":"Sonic: escalated inpatient ramp-up of sonrotoclax in CLL\/SLL and MCL","volume":"146","author":"Huang","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/6009\/2542238\/blooda_adv-2026-020392-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/6009\/2542238\/blooda_adv-2026-020392-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:50Z","timestamp":1788881570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/6009\/569310\/Safe-Accelerated-Venetoclax-Escalation-a-phase-1b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":13,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020392","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,31]]}}}